Literature DB >> 29104285

The atopic dermatitis market.

Eleni Pantazi1, Gianluca Valenza1, Manuela Hess1, Bashar Hamad1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29104285     DOI： 10.1038/nrd.2017.192

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

Authors:  J M Oldhoff; U Darsow; T Werfel; K Katzer; A Wulf; J Laifaoui; D J Hijnen; S Plötz; E F Knol; A Kapp; C A F M Bruijnzeel-Koomen; J Ring; M S de Bruin-Weller
Journal:  Allergy       Date:  2005-05       Impact factor: 13.146

2.  Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.

Authors:  Thomas Ruzicka; Jon M Hanifin; Masutaka Furue; Grazyna Pulka; Izabela Mlynarczyk; Andreas Wollenberg; Ryszard Galus; Takafumi Etoh; Ryosuke Mihara; Hiroki Yoshida; Jonathan Stewart; Kenji Kabashima
Journal:  N Engl J Med       Date:  2017-03-02       Impact factor: 91.245
  2 in total
  1 in total

1.  Feline Interleukin-31 Shares Overlapping Epitopes with the Oncostatin M Receptor and IL-31RA.

Authors:  Angelica V Medina-Cucurella; Gary F Bammert; William Dunkle; Christopher Javens; Yaqi Zhu; Veronica T Mutchler; Janet T Teel; Caitlin A Stein; Steve A Dunham; Timothy A Whitehead
Journal:  Biochemistry       Date:  2020-06-04       Impact factor: 3.162
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.